Tissue Culture Shared Resource

Home | Services & Fees | Educational Resources | Publications | Schedule

Publications

2003 2004 2005 2006 2007 2008 2009 2010 2011 2012

2004

Angeloni SV, Martin MB, Garcia-Morales P, Castro-Galache MD, Ferragut JA, Saceda M. 2004. Regulation of estrogen receptor-alpha expression by the tumor suppressor gene p53 in MCF-7 cells. J Endocrinol 180(3):497-504.

Amri, H., W. Li, K. Drieu, and V. Papadopoulos. 2004. Identification of the adrenocorticotropin and ginkgolide B-regulated 90-kilodalton protein (p90) in adrenocortical cells as a serotransferrin precursor protein homolog (adrenotransferrin). Endocrinology 145:1802-1809.

Bae, I., S. Fan, Q. Meng, J. K. Rih, H. J. Kim, H. J. Kang, J. Xu, I. D. Goldberg, A. K. Jaiswal, and E. M. Rosen. 2004. BRCA1 induces antioxidant gene expression and resistance to oxidative stress. Cancer Res 64:7893-7909.

Balasenthil, S., A. A. Sahin, C. J. Barnes, R. A. Wang, R. G. Pestell, R. K. Vadlamudi, and R. Kumar. 2004. P21-activated kinase-1 signaling mediates cyclin D1 expression in mammary epithelial and cancer cells. J Biol Chem 279:1422-1428.

Bouker, K. B., T. C. Skaar, D. R. Fernandez, K. A. O'Brien, R. B. Riggins, D. Cao, and R. Clarke. 2004. interferon regulatory factor-1 mediates the proapoptotic but not cell cycle arrest effects of the steroidal antiestrogen ICI 182,780 (faslodex, fulvestrant). Cancer Res 64:4030-4039.

Broustas, C. G., P. C. Gokhale, A. Rahman, A. Dritschilo, I. Ahmad, and U. Kasid. 2004. BRCC2, a novel BH3-like domain-containing protein, induces apoptosis in a caspase-dependent manner. J Biol Chem 279:26780-26788.

Cavalli LR, Singh B, Isaacs C, Dickson RB, Haddad BR. Loss of heterozygosity in normal breast epithelial tissue and benign breast lesions in BRCA1/2 carriers with breast cancer. 2004. Cancer Genet Cytogenet 149(1):38-43.

Cullen, K. J., Newkirk, K. A., Schumaker, L. M., Aldosari, N., Rone, J. D., and Haddad, B. R. Glutathione-S-Transferase pi amplification is associated with Cisplatin resistance in head and neck squamous cell carcinoma cell lines and primary tumors. 2004. Cancer Research 63(23):8097-102.

D'Amico, M., K. Wu, M. Fu, M. Rao, C. Albanese, R. G. Russell, H. Lian, D. Bregman, M. A. White, and R. G. Pestell. 2004. The inhibitor of cyclin-dependent kinase 4a/alternative reading frame (INK4a/ARF) locus encoded proteins p16INK4a and p19ARF repress cyclin D1 transcription through distinct cis elements. Cancer Res 64:4122-4130.

Deb, T. B., C. M. Coticchia, and R. B. Dickson. 2004. Calmodulin-mediated activation of Akt regulates survival of c-Myc-overexpressing mouse mammary carcinoma cells. J Biol Chem 279:38903-38911.

Fu, M., Wang, C., Zhang, X., and Pestell, R. G. 2004. Acetylation of Nuclear Receptors in Cellular Growth and Apoptosis. Biochemical Pharmacology 68(6):1199-208.

Fu, M., M. Rao, K. Wu, C. Wang, X. Zhang, M. Hessien, Y. G. Yeung, D. Gioeli, M. J. Weber, and R. G. Pestell. 2004. The androgen receptor acetylation site regulates cAMP and AKT but not ERK-induced activity. J Biol Chem 279:29436-29449.

Giatzakis, C. and V. Papadopoulos. 2004. Differential utilization of the promoter of peripheral-type benzodiazepine receptor by steroidogenic versus nonsteroidogenic cell lines and the role of Sp1 and Sp3 in the regulation of basal activity. Endocrinology. 145:1113-1123.

Henke RT, Haddad BR, Kim SE, Rone JD, Mani A, Jessup JM, Wellstein A, Maitra A, Riegel AT. 2004. Overexpression of the nuclear receptor coactivator AIB1 (SRC-3) during progression of pancreatic adenocarcinoma. Clin Cancer Res 10(18 Pt 1):6134-6142.

Hulit J, Wang C, Li Z, Albanese C, Rao M, Di Vizio D, Shah S, Byers SW, Mahmood R, Augenlicht LH, Russell R, Pestell RG. 2004. Cyclin D1 genetic heterozygosity regulates colonic epithelial cell differentiation and tumor number in ApcMin mice. Mol Cell Biol 24(17):7598-7611.

Jessup, J. M., L. Laguinge, S. Lin, R. Samara, K. Aufman, P. Battle, M. Frantz, K. H. Edmiston, and P. Thomas. 2004. Carcinoembryonic antigen induction of IL-10 and IL-6 inhibits hepatic ischemic/reperfusion injury to colorectal carcinoma cells. Int J Cancer 111:332-337.

Jhaveri, M. S., A. S. Rait, K. N. Chung, J. B. Trepel, and E. H. Chang. 2004. Antisense oligonucleotides targeted to the human alpha folate receptor inhibit breast cancer cell growth and sensitize the cells to doxorubicin treatment. Mol Cancer Ther. 3(12):1505-1512.

Johnson, M. D., H. Zuo, K. H. Lee, J. P. Trebley, J. M. Rae, R. V. Weatherman, Z. Desta, D. A. Flockhart, and T. C. Skaar. 2004. Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat 85:151-159.

Kim, J. S., C. Lee, A. Foxworth, and T. Waldman. 2004. B-Raf is dispensable for K-Ras-mediated oncogenesis in human cancer cells. Cancer Res 64:1932-1937.

Kumar, D., P. C. Gokhale, C. Broustas, D. Chakravarty, I. Ahmad, and U. N. Kasid. 2004. Expression of SCC-32, an anti-apoptotic molecule, correlates with enhanced proliferation and tumorigenicity of MDA-MB435 cells. Oncogene 23:612-616.

Kumar, D., I. Sakabe, S. Patel, Y. Zhang, I. Ahmad, E. A. Gehan, T. L. Whiteside, and U. Kasid. 2004. SCC-112, a novel cell cycle-regulated molecule, exhibits reduced expression in human renal carcinomas. Gene 328:187-196.

Laguinge, L. M., S. Lin, R. N. Samara, A. N. Salesiotis, and J. M. Jessup. 2004. Nitrosative stress in rotated three-dimensional colorectal carcinoma cell cultures induces microtubule depolymerization and apoptosis. Cancer Res 64:2643-2648.

Lee, C., J. S. Kim, and T. Waldman. 2004. PTEN gene targeting reveals a radiation-induced size checkpoint in human cancer cells. Cancer Res 64:6906-6914.

Liu, N., X. M. Xu, J. Chen, L. Wang, S. Yang, C. B. Underhill, and L. Zhang. 2004. Hyaluronan-binding peptide can inhibit tumor growth by interacting with Bcl-2. Int J Cancer 109:49-57.

Liu MC, Marshall JL, Pestell RG. 2004. Novel strategies in cancer therapeutics: targeting enzymes involved in cell cycle regulation and cellular proliferation. Curr Cancer Drug Targets 4(5):403-424.

Martin, M. B., S. V. Angeloni, P. Garcia-Morales, P. F. Sholler, M. D. Castro-Galache, J. A. Ferragut, and M. Saceda. 2004. Regulation of estrogen receptor-alpha expression in MCF-7 cells by taxol. J Endocrinol. 180:487-496.

Matsuo, T., T. Matsumura, M. Sakai, T. Senokuchi, M. Yano, S. Kiritoshi, K. Sonoda, D. Kukidome, R. G. Pestell, M. Brownlee, T. Nishikawa, and E. Araki. 2004. 15d-PGJ2 inhibits oxidized LDL-induced macrophage proliferation by inhibition of GM-CSF production via inactivation of NF-kappaB. Biochem.Biophys.Res Commun. 314:817-823.

Mewani, R. R., Tang, W., Rahman, A., Dritchilo, A., Ahmad, I., Kasid, U. N., and Gokhale, P. C. 2004. Enhanced therapeutic effects of doxorubicine and paclitaxel in combination with liposome-entrapped ends-modified raf antisense oligonucleotides (LErafAON) against human prostate, lung and breast tumor models. Int J Onc. 24(5):1181-1188.

Moroni, M., Soldatenkov, V., Zhang, L., Zhang, Y., Stoica, G., Gehan, E., Rashidi, B., Singh, M., Ozdemirli, M., and Mueller, S. C. 2004. Progressive Loss of Syk and Abnormal Proliferation in Breast Cancer Cells. Cancer Res 64(20):7346-7354.

Nevalainen, M. T., J. Xie, J. Torhorst, L. Bubendorf, P. Haas, J. Kononen, G. Sauter, and H. Rui. 2004. Signal transducer and activator of transcription-5 activation and breast cancer prognosis. J Clin Oncol 22:2053-2060.

Nishanian, T. G., J. S. Kim, A. Foxworth, and T. Waldman. 2004. Suppression of Tumorigenesis and Activation of Wnt Signaling by Bone Morphogenetic Protein 4 in Human Cancer Cells. Cancer Biol Ther. 3(7):667-75.

Oh, A., H. J. List, R. Reiter, A. Mani, Y. Zhang, E. Gehan, A. Wellstein, and A. T. Riegel. 2004. The nuclear receptor coactivator AIB1 mediates insulin-like growth factor I-induced phenotypic changes in human breast cancer cells. Cancer Res 64:8299-8308.

Pei, J., C. Zhang, P. C. Gokhale, A. Rahman, A. Dritschilo, I. Ahmad, and U. N. Kasid. 2004. Combination with liposome-entrapped, ends-modified raf antisense oligonucleotide (LErafAON) improves the anti-tumor efficacies of cisplatin, epirubicin, mitoxantrone, docetaxel and gemcitabine. Anticancer Drugs 15:243-253.

Pei, X. F., M. S. Noble, M. A. Davoli, E. Rosfjord, M. T. Tilli, P. A. Furth, R. Russell, M. D. Johnson, and R. B. Dickson. 2004. Explant-cell culture of primary mammary tumors from MMTV-c-Myc transgenic mice. In Vitro Cell Dev.Biol Anim 40:14-21.

Pradeep, A., C. Sharma, P. Sathyanarayana, C. Albanese, J. V. Fleming, T. C. Wang, M. M. Wolfe, K. M. Baker, R. G. Pestell, and B. Rana. 2004. Gastrin Mediated Activation of cyclin D1 Transcription Involves b-catenin and CREB pathways in Gastric Cancer Cells. Oncogene 23:3689-3699.

Rae JM, Ramus SJ, Waltham M, Armes JE, Campbell IG, Clarke R, Barndt RJ, Johnson MD, Thompson EW. 2004. Common origins of MDA-MB-435 cells from various sources with those shown to have melanoma properties. Clin Exp Metastasis 21(6):543-552.

Rizvi NA, Humphrey JS, Ness EA, Johnson MD, Gupta E, Williams K, Daly DJ, Sonnichsen D, Conway D, Marshall J, Hurwitz H. 2004. A phase I study of oral BMS-275291, a novel nonhydroxamate sheddase-sparing matrix metalloproteinase inhibitor, in patients with advanced or metastatic cancer. Clin Cancer Res 10(6):1963-1970.

Reiter, R., A. S. Oh, A. Wellstein, and A. T. Riegel. 2004. Impact of the Nuclear Receptor Coactivator AIB1 Isoform AIB1-D3 on Estrogenic Ligands with Different Intrinsic Activity. Oncogene. 23(2):403-409.

Stearns V, Coop A, Singh B, Gallagher A, Yamauchi H, Lieberman R, Pennanen M, Trock B, Hayes DF, Ellis MJ. 2004. A pilot surrogate end point biomarker trial of perillyl alcohol in breast neoplasia. Clin Cancer Res 10(22):7583-7591.

Stearns V, Gallagher A, Kleer CG, Singh B, Freedman M, Haddad BR, Isaacs C, Warren R, Brown M, Cullen J, Trock B, Hayes DF. 2004. A pilot study to establish a clinical model to perform phase II studies of breast cancer chemopreventive agents in women at high risk with biomarkers as surrogate endpoints for activity. Clin Cancer Res 10(24):8332-8340.

Suzuki M, Kobayashi H, Kanayama N, Saga Y, Suzuki M, Lin CY, Dickson RB, Terao T. 2004. Inhibition of tumor invasion by genomic down-regulation of matriptase through suppression of activation of receptor-bound pro-urokinase. J Biol Chem 279(15):14899-14908.

Thomas, M., N. Dadgar, A. Aphale, J. M. Harrell, R. Kunkel, M. Fu, R. G. Pestell, W. B. Pratt, and A. P. Lieberman. 2004. Androgen receptor acetylation site mutations cause trafficking defects, misfolding and aggregation similar to expanded glutamine tracts. J.Biol.Chem. 279:8389-8395.

Thompson EW, Waltham M, Ramus SJ, Hutchins AM, Armes JE, Campbell IG, Williams ED, Thompson PR, Rae JM, Johnson MD, Clarke R. 2004. LCC15-MB cells are MDA-MB-435: a review of misidentified breast and prostate cell lines. Clin Exp Metastasis 21(6):535-541.

Traxler P, Allegrini PR, Brandt R, Brueggen J, Cozens R, Fabbro D, Grosios K, Lane HA, McSheehy P, Mestan J, Meyer T, Tang C, Wartmann M, Wood J, Caravatti G. 2004. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res 64(14):4931-4941.

Williams, T. M., H. Lee, M. W. Cheung, A. W. Cohen, B. Razani, P. Iyengar, P. E. Scherer, R. G. Pestell, and M. P. Lisanti. 2004. Combined loss of INK4a and caveolin-1 synergistically enhances cell proliferation and oncogene-induced tumorigenesis: role of INK4a/CAV-1 in mammary epithelial cell hyperplasia. J Biol Chem 279:24745-24756.

Yu W, Pirollo KF, Yu B, Rait A, Xiang L, Huang W, Zhou Q, Ertem G, Chang EH. 2004. Enhanced transfection efficiency of a systemically delivered tumor-targeting immunolipoplex by inclusion of a pH-sensitive histidylated oligolysine peptide. Nucleic Acids Res 32(5):e48.

Zhou, X., A. Stuart, L. E. Dettin, G. Rodriguez, B. Hoel, and G. I. Gallicano. 2004. Desmoplakin is required for microvascular tube formation in culture. J Cell Sci 17:3129-3140.